Skip to content

Ozone Cardiovascular Effects in Genetically Susceptible People

Ozone Cardiovascular Effects in Genetically Susceptible People

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01192477
Acronym
OZCARD
Enrollment
80
Registered
2010-09-01
Start date
2011-05-31
Completion date
2012-08-31
Last updated
2013-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Air pollution, Ozone, Health effects of ozone exposure

Brief summary

Increases in air pollution are associated with increases in deaths from cardiovascular disease, but the investigators know little about how ozone air pollution affects the cardiovascular system. The investigators proposed study will determine the effects of ozone on blood vessel and heart function that could worsen illness in people with underlying heart disease. This will be accomplished by studying healthy volunteers who inhale ozone in a controlled clinical study, and also by studying their exposure to ozone and other pollutants during their normal daily activities. The investigators will study volunteers who may be at increased risk for the effects of ozone because of genetic susceptibility. Understanding the effects of ozone on the heart and circulation can help establish appropriate air pollution standards, and provide strategies to protect the most susceptible people.

Interventions

OTHEROzone

All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.

Sponsors

National Institute of Environmental Health Sciences (NIEHS)
CollaboratorNIH
Conservation of Clean Air and Water in Europe (CONCAWE)
CollaboratorUNKNOWN
Exxon Mobil
CollaboratorINDUSTRY
University of Rochester
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy, * Never-smokers with normal spirometry based on the standards published by Morris and co-workers (Morris et al. 1971), and * A normal electrocardiogram. -

Exclusion criteria

* Any history of habitual smoking. * Marijuana smoking within the past 5 years. * Pregnancy. * Any history of significant organ impairment, chronic respiratory disease, ischemic heart disease, active psychiatric disorder or current drug or alcohol abuse. * Occupation involving regular, heavy dust or particle exposure, such as welding, mining, foundry work. * FEV1 \< 75% of predicted at baseline screening. * Subjects with atopy or allergic rhinitis will not be excluded as long as they do not require regular treatment with antihistamines or systemic steroids. * Subjects on certain prescription medications such as prednisone or statins will be excluded. Use of other medications will be considered on an individual basis. Subjects will not be asked to discontinue prescription medications for the purposes of this study. * Hypertension (blood pressure higher than 140/90 mmHg or on antihypertensive medication). * Subject lives outside the Rochester metropolitan area.

Design outcomes

Primary

MeasureTime frameDescription
Nitric oxide bioavailabilityBefore and 3 hours after ozone exposureWe hypothesize that systemic vascular effects of exposure to ozone will be reflected in reductions in arterial blood nitrite or its A/V gradient. This will require simultaneous collection of venous and arterial blood.

Secondary

MeasureTime frameDescription
Evidence of endothelial injuryBefore and 3 hours after ozone exposureWe hypothesize that systemic vascular effects of exposure to ozone will alter markers of vascular function and inflammation. Flow cytometry will be used to detect activated platelets and pro-coagulant circulating microparticles.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026